J Med Life Sci.
2024 May;21(2):40-48. 10.22730/jmls.2024.21.2.40.
Effectiveness of statin treatment for recurrent stroke according to stroke subtypes
- Kye MS
1,2 - Kim DY3,4,5
- Kang DW3,4,5
- Kim BK3,4,5
- Park JH3,4,5
- Guk HS3
- Kim N3
- Choi SW3
- Lee D3
- Ko Y3
- Kim JY3
- Kang J3
- Kim BJ3
- Han MK3
- Bae HJ3
- CRCS-K-NIH investigators1
- Affiliations
-
- 1Department of Neurology, Seongnam Citizens Medical Center, Seongnam, Republic of Korea
- 2Seoul Singil Rehabilitation Clinic, Seoul, Republic of Korea
- 3Department of Neurology and Cerebrovascular Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
- 4Department of Neurology, Gyeonggi Provincial Medical Center Icheon Hospital, Icheon, Republic of Korea
- 5Headquarters for Public Health Care, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
- KMID: 2561954
- DOI: http://doi.org/10.22730/jmls.2024.21.2.40
Abstract
- Understanding the effectiveness of statin treatment is essential for developing tailored stroke prevention strategies. We aimed to evaluate the efficacy of statin treatment in preventing recurrent stroke among patients with various ischemic stroke subtypes. Using data from the Clinical Research Collaboration for Stroke-Korea-National Institute for Health (CRCS-K-NIH) registry, we included patients with acute ischemic stroke admitted between January 2011 and July 2020. To evaluate the differential effects of statin treatment based on the ischemic stroke subtype, we analyzed patients with large artery atherosclerosis (LAA), cardio-embolism (CE), and small vessel occlusion (SVO). The primary outcomes were recurrent ischemic stroke and recurrent stroke events. The hazard ratio for outcomes between statin users and nonusers was compared using a Cox proportional hazards model adjusted for covariates. A total of 46,630 patients who met the inclusion criteria were analyzed. Statins were prescribed to 92%, 93%, and 78% of patients with LAA, SVO, and CE subtypes, respectively. The hazards of recurrent ischemic stroke and recurrent stroke in statin users were reduced to 0.79 (95% confidence interval [CI], 0.63-0.99) and 0.77 (95% CI, 0.62-0.95) in the LAA subtype and 0.63 (95% CI, 0.52-0.76) and 0.63 (95% CI, 0.53-0.75) in CE subtype compared to nonusers. However, the hazards of these outcomes did not significantly decrease in the SVO subtype. The effectiveness of statin treatment in reducing the risk of recurrent stroke in patients with LAA and CE subtypes has been suggested. Nonetheless, no significant effect was observed in the SVO subtype, suggesting a differential effect of statins on different stroke subtypes.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Do Statins Help Prevent VTE After Hemorrhagic Stroke During the Acute Period?
- Cerebrovascular Disease : Overview and Classification
- Secondary Prevention as Integral Part of Stroke Rehabilitation
- Recent updates in dyslipidemia management: perspectives in stroke-specific situation
- Transesophageal Echocardiographic Findings in Stroke Subtypes
